Canada markets closed

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.55000.0000 (0.00%)
At close: 04:00PM EST
0.5500 0.00 (0.00%)
After hours: 07:17PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5500
Open0.5450
Bid0.5408 x 900
Ask0.5500 x 1200
Day's Range0.5500 - 0.5598
52 Week Range0.0920 - 0.6200
Volume309,617
Avg. Volume672,189
Market Cap17.32M
Beta (5Y Monthly)1.70
PE Ratio (TTM)1.45
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSept 21, 2022
1y Target EstN/A
  • GlobeNewswire

    Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the rec

  • GlobeNewswire

    Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend

  • GlobeNewswire

    Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

    Company to Announce a Record Date for Initial Distribution in Due CourseSOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company. “With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this inf